NCT02627417Unknown3 期
Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 216
- 试验地点
- 1
- 主要终点
- Overall response-rate.
研究概览
简要总结
Due to its expected efficacy based on the retrospective data available in ITP, its relatively good safety profile and its very low cost , dapsone could be a good steroid-sparing second-line option for adults with ITP.
This study is a phase III prospective multicenter randomized open trial comparing two treatment strategies:
- Arm A (experimental arm): prednisone at 1 mg/kg for 3 weeks + dapsone at 100 mg per day up to week 52 if an initial response is achieved.
- Arm B (control arm): prednisone alone at 1 mg/kg for 3 weeks followed by monitoring and "standard of care" The aim of the study is to demonstrate the efficacy of dapsone based on the overall response rate (including response and complete response) as a second-line treatment for adults with newly-diagnosed persistent or chronic (modified by amendment 08/11/2016) ITP not achieving a durable response with corticosteroids. The primary endpoint will be the overall response-rate (response or complete response according to standard definitions) in both arms at week 52 (1 year).
The secondary endpoints are the following :
- To assess the safety of dapsone over the study period and especially the incidence of cutaneous reactions.
- To analyze the overall response rate (platelet count > 30 x 109/L with at least a doubling of the pre-treatment count in the absence of any other ITP treatment) in both treatment arms at week 24.
- To compare the rate of complete response and failure in both arms at 24 and 52 weeks.
- To compare time to treatment failure (TTF) in both arms
- To investigate the mechanisms of action of dapsone in ITP in a subgroup of patients (ancillary study)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Diagnosis of primary ITP according to the standard definition and international guidelines.
- •Previous transient response to corticosteroids ± intravenous immunoglobulin defined by an increase of the platelet count above 30 x 109/L with at least a twofold increase of the pre-treatment count.
- •At least platelet count ≤ 30 x 109/L within the 2 weeks before inclusion with a platelet count at time of inclusion below 50 x 109/L, or platelet count < 50 x 109/L at any time point in patients requiring treatment (i.e., patients with bleeding symptoms, elderly patients with comorbidities and/or patients on aspirin for example, or other reason at the investigator discretion) (modified by amendment 8/11/2016)
- •Normal marrow aspirate for patients aged of 60 and above.
- •Negative pregnancy test and effective method of contraception for women of childbearing age over the study period.
- •Informed consent.
- •Patient affiliated to the French National Social Security System
排除标准
- •Secondary ITP. Patients with positive antinuclear antibodies and/or positive antiphospholipid antibodies not fulfilling the classification criteria for systemic lupus erythematosus and/or antiphospholipid antibody syndrome will not be excluded.
- •Platelet count ≥ 50 x 109/L or between 30 and 50 x 109/L and no bleeding symptoms and no need for treatment (modified by amendment 8/11/2016)
- •Severe bleeding manifestations defined a bleeding score ≥ 8
- •No previous transient response to corticosteroids ± intravenous immunoglobulin.
- •Previous ITP treatment other than corticosteroids and intravenous immunoglobulin (including rituximab and splenectomy).
- •Active severe infection or history of severe infection within 4 weeks before inclusion.
- •History of allergy to sulfonamides.
- •Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- •History of methemoglobinemia
- •Hemoglobin level < 11g/dL and/or neutrophil count < 1,500/ gL.
- •History of autoimmune (Evans' syndrome) or hereditary haemolytic anemia.
- •Liver or kidney function impairment (creatinine clearance < 30 ml/min, ALT, AST >2 times upper normal limit). (modified by amendment 8/11/2017)
- •Hepatitis C virus (HCV) Ab, HIV Ab, HBsAg, seropositive status. (modified by amendment 8/11/2017)
- •Concomitant medical condition requiring anticoagulation. (modified by amendment 8/11/2017)
- •Pregnancy or lactation.
研究组 & 干预措施
Dapsone: (Disulone®)
Experimental
Dapsone: Disulone® given orally at 100 mg per day
干预措施: Dapsone (Disulone®) (Drug)
Dapsone: (Disulone®)
Experimental
Dapsone: Disulone® given orally at 100 mg per day
干预措施: Prednisone (Cortancyl®) (Drug)
Prednisone (Cortancyl®) alone and "standard of care"
Active Comparator
Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and "standard of care" (control arm)
干预措施: Prednisone (Cortancyl®) alone followed by monitoring and "standard of care" (Drug)
结局指标
主要结局
Overall response-rate.
时间窗: at week 52
次要结局
- Assess the safety of dapsone especially the incidence of cutaneous adverse effects.(over the study period (up to 52 weeks))
- Compare the overall response rate .(at week 24)
- Proportion of non-responders patients (primary failure)(at 24 and at 52 weeks)
- Proportion of patients with complete response in both arms, defined as follows: - Proportion of patients with a platelet count > 100 x 109/L in the absence use of any other ITP directed therapies(at 24 and at 52 weeks)
- Number of days to treatment failure in both arms(over the study period (up to 52 weeks))
- Mechanisms of action of Dapsone: degree of phagocytosis of autologous platelets and red blood cells, cytokines profile expression (including IL-8), whole blood gene expression signature between responders and non-responders.(over the study period (52 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya ReservoirLeptomeningeal MetastasisLung CancerNCT06399926Xiangya Hospital of Central South University64
已完成
不适用
Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip AugmentationAbnormal LipNCT04917588Croma-Pharma GmbH114
招募中
不适用
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimensChronic Lymphocytic Leukemia (CLL)NL-OMON23205HOVON data center70
暂停
4 期
TEM-PCR™ Prospective Clinical Utility StudyUpper Resp Tract InfectionNCT04248361Diatherix Laboratories, LLC314
已完成
3 期
An Evaluation of Etanercept in the Treatment of Subjects With PsoriasisPsoriasisNCT00111111Amgen